Physiologically-Based Pharmacokinetic Modeling to Support Pediatric Clinical Development: An IQ Working Group Perspective on the Current Status and Challenges
The paper reviews current applications of pediatric PBPK across therapeutic areas and outlines where PBPK…
Certara2025 年 11 月 21 日
Pregnant women, long excluded from drug trials, are back in the spotlight
Certara’s Karen Yeo discusses FDA’s draft guidance to include pregnant and breastfeeding women in clinical…
Certara2025 年 10 月 17 日
Essentials of model-informed drug development in oncology
Model-informed drug development in oncology is critical to developing safer and more effective cancer drugs.…
Certara2025 年 10 月 6 日
Certara Launches DIDB® Concomitant Meds Navigator, Extending Leadership in Drug Interaction Science
Meet DIDB Concomitant Meds Navigator—an evidence-based tool to identify contraindicated or monitored co-medications and manage…
Certara2025 年 9 月 22 日
Certara Launches Libra™: AI-Powered Drug-Induced Liver Injury Prediction Tool
RADNOR, Pa. – 2025 年 9 月 17 日 – Certara, Inc. （纳斯达克股票代码：CERT), a global leader in…
Certara2025 年 9 月 17 日
Modeling Approaches for Determination of Pharmacokinetics/Pharmacodynamics
Explore insights from Certara experts on how PK/PD modeling streamlines biologic drug development.
Certara2025 年 8 月 5 日
